论文部分内容阅读
1例29岁男性患者因双相情感障碍服用富马酸喹硫平（维持剂量：0.2 g、2次/d）与丙戊酸镁缓释片（维持剂量：0.5 g、2次/d）治疗。9 d后，患者精神症状好转，未发生不良反应，喹硫平血药浓度为379 μg/L。因并发化脓性中耳炎，加用克拉霉素（0.25 g口服、2次/d）。次日晨患者出现昏睡状态，喹硫平血药浓度升至614 μg/L。考虑为克拉霉素与喹硫平相互作用所致。停用富马酸喹硫平和克拉霉素，给予静脉输液加快药物代谢。第2天患者昏睡状态消失，继续服用原剂量富马酸喹硫平与丙戊酸镁缓释片，抗菌药物换用头孢地尼胶囊0.1 g口服、3次/d，未再出现不适症状。“,”A 29-year-old male patient was treated with quetiapine fumarate (maintenance dose: 0.2 g twice daily) and magnesium valproate sustained release tablets (maintenance dose: 0.5 g twice daily) for bipolar affective disorder. After 9 days of treatments, the patient′s psychiatric symptoms were improved, no adverse reactions occurred, and plasma concentration of quetiapine was 379 μg/L. Clarithromycin 0.25 g orally twice daily was added because of concurrent suppurative otitis media. The next morning, the patient developed lethargy and the blood concentration of quetiapine increased to 614 μg/L, which was considered to be caused by the interaction of clarithromycin and quetiapine. Quetiapine fumarate and clarithromycin were discontinued and intravenous fluids were given to accelerate drug metabolism rate. On the 2nd day, the patient′s lethargy disappeared. Quetiapine fumarate at the original dose was given, magnesium valproate sustained-release tablets were continued, and the antimicrobial drug was switched to cefdinir capsules 0.1 g orally thrice daily. Then the symptoms above-mentioned did not recur.